Omnicell (NASDAQ:OMCL) Trading 4.7% Higher – Here’s Why

Omnicell, Inc. (NASDAQ:OMCL) rose 4.7% during mid-day trading on Monday . The stock traded as high as $34.88 and last traded at $34.62. 429,069 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 663,429 shares. The stock had previously closed at $33.08.

Analysts Set New Price Targets

A number of brokerages have commented on OMCL. KeyCorp restated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Piper Sandler reiterated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Finally, Wells Fargo & Company reduced their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Stock Up 5.2%

The stock has a market capitalization of $1.58 billion, a P/E ratio of 41.44, a P/E/G ratio of 0.83 and a beta of 0.98. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The stock’s 50 day simple moving average is $39.80 and its 200 day simple moving average is $39.35.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, research analysts predict that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Institutional Trading of Omnicell

Several institutional investors and hedge funds have recently bought and sold shares of OMCL. Nykredit A S acquired a new position in shares of Omnicell in the 2nd quarter worth approximately $26,000. Raymond James Financial Inc. acquired a new stake in shares of Omnicell during the 2nd quarter valued at approximately $26,000. Versant Capital Management Inc raised its position in shares of Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after acquiring an additional 294 shares in the last quarter. Clearstead Advisors LLC lifted its stake in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in Omnicell during the fourth quarter worth $58,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.